RAB27A is a member of the Rab GTPase family, regulating vesicle docking, fusion, and secretion in processes such as cytotoxic granule exocytosis in lymphocytes . Mutations in RAB27A are linked to Griscelli syndrome type 2 (GS2) and hemophagocytic lymphohistiocytosis (HLH) . The HRP-conjugated RAB27A antibody allows direct visualization of this protein in experimental assays, eliminating the need for secondary antibodies and streamlining workflows.
The Rab27a Antibody (E-8): sc-74586 from Santa Cruz Biotechnology is a well-characterized HRP-conjugated monoclonal antibody.
This antibody exhibits no cross-reactivity with unrelated Rab proteins .
Detects RAB27A at 26–32 kDa in lysates from K562 (chronic myelogenous leukemia) and U-87 MG (glioblastoma) cell lines .
Specificity confirmed using RAB27A knockout (KO) cell lines, showing reduced or absent bands compared to wild-type controls .
Localizes RAB27A to cytoplasmic compartments in formalin-fixed, paraffin-embedded human lymphoma tissues .
Used at concentrations of 2–10 µg/mL for optimal signal-to-noise ratios .
Cancer Research: RAB27A promotes colorectal cancer (CRC) proliferation and invasion via ERK/MAPK pathway activation .
Immunology: Critical for secretory lysosome exocytosis in hematopoietic cells; dysregulation causes HLH .
HRP-conjugated RAB27A antibodies are pivotal in studying: